Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fitusiran Prophylaxis in Male Pediatric Subjects With Hemophilia A or B
NCT03974113Phase 3Completed
- Sponsor
- Sanofi
- Start
- Jan 2020
- Primary completion
- Aug 2026
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 6
01
Overview
A Phase 3 trial of fitusiran in hemophilia A, hemophilia B (HB), sponsored by Sanofi. Started Jan 2020; status: completed.
02
Drugs
fitusiran
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT03974113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03974113.